Movement-related symptoms in Parkinson’s disease (PD) and other neurological conditions arise from irregular electrical signals in the brain regions responsible for motor control. Deep brain stimulation (DBS), approved since 1997 by the FDA presents a transformative treatment option for PD patients as medications lose efficacy and side-effects from symptom fluctuations increase.
By combining brain-implanted electrodes with a pacemaker-like device implanted under the skin of the upper chest, patients often achieve remarkable symptom relief.
Although approved for over 30 years the current DBS therapy still lacks automatic adaptability to states such as sleep, specific symptoms such as bradykinesia, or side-effects such as hyperkinesia. This can lead to challenges for patients and their quality of life, as the constant level of stimulation doesn't match symptom volatility.
Next generation adaptive DBS therapy, in which stimulation strength adjusts automatically to symptoms, promises to solve these problems.
Common stimulation-related adverse effects
01
Prokinetic movement
02
Speech impairment
03
Cognitive side effects
We are bringing symptom and neural state decoding to DBS
Delivering generalized decoding models for personalized adaptive deep brain stimulation
Meet the Team
A unique team of clinical and technical experts
Join us
Team Members
Research software engineers
Machine learning engineers
Regulatory affairs specialist
Cooperations
Medical device manufacturers
Hospitals for solution testing
Other ideas in mind?
Contact us below!